Cancer Family
Musculoskeletal Neoplasm
CI-CAN-00000278Explore in graph →
Non-malignant212 active trials5 approved drugs54 evidence items
- NCIt
- C166354
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000278Explore in graph →
Clinical trials
1,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | withdrawn | Phase 2 | 0 | David Liebner, MDOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT00095017 |
| Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083) |
| withdrawn |
| Phase 2 |
| 0 |
| Organon and CoINDUSTRY |
| 0 |
| Feb 16, 2022 |
| clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT00478270 | A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease. | withdrawn | Phase 2 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00851162 | Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions | withdrawn | Phase 2 / Phase 3 | 0 | Emory UniversityOTHER | 1 | Nov 28, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 1, 2025source: clinicaltrials